Five critical regulatory issues pharma counsel can't ignore - Lexology Pro

# Strengthening AI Governance: Essential Steps for Pharmaceutical Companies As artificial intelligence becomes increasingly embedded in pharmaceutical operations, regulatory scrutiny is intensifying. Companies can no longer afford to take a passive approach to AI compliance. For pharma counsel and leadership teams, building robust AI literacy and governance frameworks isn't just recommended—it's critical for mitigating regulatory risk and maintaining stakeholder trust. The foundation of effective AI governance starts with comprehensive visibility. Organizations must systematically map their AI models and data flows to understand where and how AI touches their operations. This mapping exercise should be paired with rigorous audits of datasets and third-party vendors to identify potential vulnerabilities, biases, or compliance gaps. Without this baseline understanding, companies operate in a dangerous blind spot that regulators are increasingly prepared to examine. Documentation and transparency form the second pillar of AI readiness. Pharma companies need formal governance frameworks that clearly define roles, responsibilities, and oversight mechanisms for AI deployment. Equally important is updating vendor contracts to include explicit transparency requirements, audit rights, and accountability measures. These contractual safeguards ensure that third-party AI providers meet the same rigorous standards your organization maintains internally. The regulatory landscape for AI in pharmaceuticals will only grow more complex. Companies that proactively invest in AI literacy, implement comprehensive governance structures, and enforce transparency throughout their vendor ecosystem will be best positioned to navigate this evolving terrain successfully. #AIGovernance #PharmaTech #RegulatoryCompliance #HealthcareAI

# Strengthening AI Governance: Essential Steps for Pharmaceutical Companies

As artificial intelligence becomes increasingly embedded in pharmaceutical operations, regulatory scrutiny is intensifying. Companies can no longer afford to take a passive approach to AI compliance. For pharma counsel and leadership teams, building robust AI literacy and governance frameworks isn't just recommended—it's critical for mitigating regulatory risk and maintaining stakeholder trust.

The foundation of effective AI governance starts with comprehensive visibility. Organizations must systematically map their AI models and data flows to understand where and how AI touches their operations. This mapping exercise should be paired with rigorous audits of datasets and third-party vendors to identify potential vulnerabilities, biases, or compliance gaps. Without this baseline understanding, companies operate in a dangerous blind spot that regulators are increasingly prepared to examine.

Documentation and transparency form the second pillar of AI readiness. Pharma companies need formal governance frameworks that clearly define roles, responsibilities, and oversight mechanisms for AI deployment. Equally important is updating vendor contracts to include explicit transparency requirements, audit rights, and accountability measures. These contractual safeguards ensure that third-party AI providers meet the same rigorous standards your organization maintains internally.

The regulatory landscape for AI in pharmaceuticals will only grow more complex. Companies that proactively invest in AI literacy, implement comprehensive governance structures, and enforce transparency throughout their vendor ecosystem will be best positioned to navigate this evolving terrain successfully.

#AIGovernance #PharmaTech #RegulatoryCompliance #HealthcareAI

Original Source

Action: Boost AI literacy. Map models and data flows, audit datasets and vendors, and document governance. Update contracts with transparency and ...